Search results for "INTERFERON"

showing 10 items of 963 documents

Azithromycin Differentially Alters TCR-Activated Helper T Cell Subset Phenotype and Effector Function

2020

In addition to their antibiotic activities, azithromycin (AZM) exhibits anti-inflammatory effects in various respiratory diseases. One of the potent anti-inflammatory mechanisms is through inhibition of CD4+ helper T (Th) cell effector function. However, their impact on specific Th subset is obscure. Herein, we demonstrate the cellular basis of phenotypic and functional alterations associated with Th subsets following AZM treatment in vitro. Using well-characterized Th subset specific chemokine receptors, we report significant suppression of T cell receptor (TCR)-stimulated hyperactivated CCR4+CXCR3+ (Th0) expansion compared to CCR4-CXCR3+ (Th1-like) and CCR4+CXCR3- (Th2-like) cells. Intere…

lcsh:Immunologic diseases. Allergy0301 basic medicineReceptors CCR4Receptors CXCR3Receptor expressionImmunologyReceptors Antigen T-CellBiologyCXCR303 medical and health sciencesChemokine receptorInterferon-gamma0302 clinical medicineDownregulation and upregulationCell MovementT-Lymphocyte SubsetsImmunology and AllergyHumansIFN-γInterleukin 4Cells CulturedOriginal Researchanti-inflammatoryazithromycinCD4+ helper T cellsCXCR3EffectorCell growthT-cell receptorIL-4apoptosisCell DifferentiationBacterial InfectionsTh1 CellsHealthy VolunteersCell biologyAnti-Bacterial Agents030104 developmental biologyCCR4Interleukin-4lcsh:RC581-607030215 immunologyFrontiers in Immunology
researchProduct

IFI16 expression is related to selected transcription factors during B-cell differentiation

2015

The interferon-inducible DNA sensor IFI16 is involved in the modulation of cellular survival, proliferation, and differentiation. In the hematopoietic system, IFI16 is consistently expressed in the CD34+ stem cells and in peripheral blood lymphocytes; however, little is known regarding its regulation during maturation of B- and T-cells. We explored the role of IFI16 in normal B-cell subsets by analysing its expression and relationship with the major transcription factors involved in germinal center (GC) development and plasma-cell (PC) maturation.IFI16mRNA was differentially expressed in B-cell subsets with significant decrease inIFI16mRNA in GC and PCs with respect to naïve and memory subs…

lcsh:Immunologic diseases. AllergyAdultMaleXBP1Article SubjectLymphoid TissueTranscription FactorCellular differentiationPlasma CellsImmunologyB-Lymphocyte SubsetsBiologySettore MED/08 - Anatomia PatologicaAdult; B-Lymphocyte Subsets; B-Lymphocytes; Enzyme Activation; Female; Gene Expression Profiling; Germinal Center; Humans; Lymphoid Tissue; Male; NF-kappa B; Nuclear Proteins; Phosphoproteins; Plasma Cells; RNA Messenger; Transcription Factors; Cell Differentiation; Gene Expression Regulation; Immunology; Immunology and AllergyGene expressionImmunology; Immunology and AllergyHumansImmunology and AllergyRNA MessengerTranscription factorB-Lymphocyte SubsetsNuclear ProteinRegulation of gene expressionB-Lymphocyte SubsetB-LymphocytesRELBGene Expression ProfilingB-LymphocyteNF-kappa BNuclear ProteinsCell DifferentiationGeneral MedicineB-Cell DifferentiationPhosphoproteinsGerminal CenterMolecular biologyGene expression profilingEnzyme ActivationGene Expression RegulationPhosphoproteinImmunology interferon-inducible DNA sensor IFI16 B-Cell DifferentiationPlasma Cellinterferon-inducible DNA sensor IFI16Femalelcsh:RC581-607Transcription FactorsResearch ArticleHuman
researchProduct

Interleukin 10 restores lipopolysaccharide-induced alterations in synaptic plasticity probed by repetitive magnetic stimulation

2020

Systemic inflammation is associated with alterations in complex brain functions such as learning and memory. However, diagnostic approaches to functionally assess and quantify inflammation-associated alterations in synaptic plasticity are not well-established. In previous work, we demonstrated that bacterial lipopolysaccharide (LPS)-induced systemic inflammation alters the ability of hippocampal neurons to express synaptic plasticity, i.e., the long-term potentiation (LTP) of excitatory neurotransmission. Here, we tested whether synaptic plasticity induced by repetitive magnetic stimulation (rMS), a non-invasive brain stimulation technique used in clinical practice, is affected by LPS-induc…

lcsh:Immunologic diseases. AllergyLipopolysaccharides0301 basic medicinenon-invasive brain stimulationInterleukin-1betaImmunologyTNFα-reporter mouseMice TransgenicStimulationNeurotransmissionHippocampusSynaptic TransmissionneuroinflammationInterferon-gammaMice03 medical and health sciences0302 clinical medicineGenes Reportertranscranial magnetic stimulationAnimalsImmunology and Allergyddc:610NeuroinflammationOriginal ResearchInflammationNeuronsNeuronal Plasticitysynaptic plasticityInterleukin-6Tumor Necrosis Factor-alphaChemistryLong-term potentiationInterleukin-10Mice Inbred C57BLOrganoids030104 developmental biologyBrain stimulationSynaptic plasticityExcitatory postsynaptic potentialTumor necrosis factor alphaMicrogliainterleukin 10lcsh:RC581-607Neuroscience030217 neurology & neurosurgery
researchProduct

Interleukin-12 in Human Boutonneuse Fever Caused by Rickettsia conorii

2000

Interleukin (IL)-12 contributes to the resistance against a number of intracellular pathogens. We examined the potential biological role of IL-12 by studying peripheral blood mononuclear cells (PBMC), its production and its effect on cytokine synthesis in 20 Sicilian patients with boutonneuse fever (BF) caused by Rickettsia conorii. Data indicate that PBMC from acute BF patients were able to produce IL-12 in response to in vitro stimulation with rickettsial antigen (Ag): this production was higher than that detected in healed patients. Monocytes were the main source of IL-12 by PBMC from BF patients. IL-12 secretion by in vitro Ag-stimulated PBMC from BF patients was potentiated by recombin…

medicine.drug_classImmunologyInterleukinGeneral MedicineRecombinant Interferon GammaBiologyBoutonneuse Fevermedicine.diseaseMonoclonal antibodybiology.organism_classificationInterleukin-12Peripheral blood mononuclear cellInterleukin-10Boutonneuse feverInterferon-gammaRickettsia conoriiImmunityImmunologyLeukocytes MononuclearmedicineInterleukin 12HumansInterleukin-4Rickettsia conoriiScandinavian Journal of Immunology
researchProduct

Interleukin-15, as Interferon-gamma, Induces the Killing of Leishmania infantum in Phorbol-Myristate-Acetate-Activated Macrophages Increasing Interle…

2004

The potential leishmanicidal activity of interleukin-15 (IL-15) was examined while priming with the cytokine phorbol-myristate-acetate (PMA)-activated macrophages and infecting them with Leishmania infantum parasites. The activation of macrophage cultures with IL-15 determined a significant anti-leishmanial activity, comparable with that induced by interferon-gamma (IFN-gamma). The killing of Leishmania in macrophages primed with IL-15, as well as with IFN-gamma, was followed by an increase in the IL-12 synthesis. The neutralization of IL-15 or IFN-gamma, by specific monoclonal antibodies (MoAb) caused a significant reduction in leishmanicidal activity. Furthermore, in PMA-activated macroph…

medicine.drug_classmedicine.medical_treatmentImmunologyMonoclonal antibodyNeutralizationMicrobiologyInterferon-gammaMicemedicineAnimalsInterferon gammaLeishmania infantumInterleukin-15biologyActivator (genetics)MacrophagesGeneral Medicinebiology.organism_classificationInterleukin-12CytokineInterleukin 15Interleukin 12Leishmaniasis VisceralTetradecanoylphorbol AcetateLeishmania infantummedicine.drugScandinavian Journal of Immunology
researchProduct

Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity

2021

AbstractBackgroundMultiple sclerosis (MS) disease risk is associated with reduced sun exposure. This study assessed the relationship between measures of sun-exposure (vitamin D (vitD), latitude) and MS disease severity, the mechanisms of action, and effect-modification by medication and sun-sensitivity associated MC1R variants.MethodsTwo multi-center cohort studies (nNationMS=946, nBIONAT=991). Outcomes were the multiple sclerosis severity score (MSSS) and the number of Gd-enhancing lesion (GELs). RNAseq of four immune cell populations before and after UV-phototherapy of five MS patients.ResultsHigh serum vitD was associated with reduced MSSS (PNationMS=0.021; PBIONAT=0.007) and reduced ris…

medicine.medical_specialty610 Medicine & healthDiseaseGastroenterologyLesionImmune systemInterferonInternal medicineVitamin D and neurologyMedicineddc:610610 Medicine & healthBeneficial effectsSunlightSystemic lupus erythematosusMultidisciplinaryLow latitudebusiness.industryMultiple sclerosismedicine.diseaseddc:Cardiovascular and Metabolic DiseasesDisease riskmedicine.symptombusinessmedicine.drugCohort study
researchProduct

IFN-alpha Stimulates Proliferation and Cytokine Secretion of CD40-Stimulated B Cell Chronic Lymphocytic Leukemia Cells In Vitro

1999

Interferon (IFN)-alpha has a therapeutic effect in several B cell malignancies, including low-grade non-Hodgkin's lymphoma (NHL), multiple myeloma, and hairy cell leukemia, whereas its efficacy in the treatment of B cell chronic lymphocytic leukemia (B-CLL) is rather limited. In the present study, we investigated the effect of IFN-alpha on the biologic functions of B-CLL cells, which were stimulated by cross-linking of the CD40 antigen. In cell samples from 16 B-CLL patients, the addition of IFN-alpha to CD40-stimulated purified B-CLL cells caused a significant increase in [3H]thymidine uptake (p < 0.003). In B-CLL cells maximally activated by CD40 cross-linking and interleukin-2 (IL-2)/IL-…

medicine.medical_specialtyAdoptive cell transferImmunologyNaive B cellAntineoplastic Agentsimmune system diseaseshemic and lymphatic diseasesVirologyInternal medicineTumor Cells CulturedmedicineHumansHairy cell leukemiaCD40 AntigensCells CulturedB cellCD20B-LymphocytesCD40biologyChemistryInterferon-alphaCell Biologymedicine.diseaseLeukemia Lymphocytic Chronic B-CellStimulation ChemicalClone CellsEndocrinologymedicine.anatomical_structurebiology.proteinCancer researchCytokinesCytokine secretionDrug Screening Assays AntitumorCD5Cell DivisionJournal of Interferon &amp; Cytokine Research
researchProduct

Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk

2017

BACKGROUND In patients with chronic hepatitis C infection, a sustained virologic response (SVR) to interferon-based therapy markedly decreases the incidence of hepatocellular carcinoma (HCC) over the long term. This is also true for patients who have hepatic cirrhosis, as well as for those with HCC-with or without cirrhosis-who have undergone resection or ablation with curative intent. Recent publications, however, have reported a higher incidence of HCC among patients in both of these subgroups who were treated with direct antiviral agents (DAA) rather than interferon-based therapy. METHODS A selective search for pertinent literature was carried out in the PubMed database with the search t…

medicine.medical_specialtyCarcinoma HepatocellularCirrhosisHepatitis C virusReview Articlemedicine.disease_causeAntiviral AgentsGastroenterology03 medical and health sciencesDrug treatment0302 clinical medicineChronic hepatitisRisk FactorsInterferonInternal medicinemedicineHumansbusiness.industryIncidence (epidemiology)Liver NeoplasmsGeneral MedicineHepatitis C Chronicmedicine.diseasedigestive system diseasesTumor progression030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyNeoplasm Recurrence Localbusinessmedicine.drugDeutsches Ärzteblatt international
researchProduct

Management of hepatitis C virus genotype 4: recommendations of an international expert panel.

2011

HCV has been classified into no fewer than six major genotypes and a series of subtypes. Each HCV genotype is unique with respect to its nucleotide sequence, geographic distribution, and response to therapy. Genotypes 1, 2, and 3 are common throughout North America and Europe. HCV genotype 4 (HCV-4) is common in the Middle East and in Africa, where it is responsible for more than 80% of HCV infections. It has recently spread to several European countries. HCV-4 is considered a major cause of chronic hepatitis, cirrhosis, hepatocellular carcinoma, and liver transplantation in these regions. Although HCV-4 is the cause of approximately 20% of the 170 million cases of chronic hepatitis C in th…

medicine.medical_specialtyCarcinoma HepatocellularGenotypeHepatitis C virusHepacivirusHepacivirusmedicine.disease_causeAntiviral AgentsPolymorphism Single NucleotideFlaviviridaeInternal medicineGenotypeEpidemiologyRibavirinmedicineHumansClinical Trials as TopicHepatologybiologybusiness.industryInterleukinsLiver Neoplasmsvirus diseasesHepatitis CHepatitis C Chronicbiology.organism_classificationmedicine.diseaseVirologydigestive system diseasesRecombinant ProteinsLiver TransplantationNatural historyHepatocellular carcinomaInterferon Type IPractice Guidelines as TopicHCVInterferonsbusiness
researchProduct

High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C

2001

Background: Therapy of chronic hepatitis C non- responders to interferon monotherapy with standard doses of interferon plus ribavirin is usually ineffective. Aim: To evaluate the efficacy and tolerability of high-dose prolonged combination retreatment in non- responder patients. Methods: Patients were retreated for 6 months with 6 MU αIFN on alternate days and 1000 or 1200 mg/day ribavirin. HCV-RNA negative patients continued therapy for an additional 6 months. Results: Forty patients (29 males, mean age 49.7 years, 34 genotype 1b, 11 with F3 fibrosis) were treated. At 6 months, 20 (50%) patients were HCV-RNA negative but six of them discontinued therapy because of adverse events. A sustain…

medicine.medical_specialtyChemotherapyHepatologyCombination therapybusiness.industrymedicine.medical_treatmentRibavirinGastroenterologyAlpha interferonGastroenterologySurgerychemistry.chemical_compoundRegimenchemistryTolerabilityInternal medicinemedicinePharmacology (medical)Adverse effectbusinessInterferon alfamedicine.drugAlimentary Pharmacology &amp; Therapeutics
researchProduct